Skip to main content
NGL Fine Chem Ltd. logo

NGL Fine Chem Ltd. — Investor Relations & Filings

Ticker · NGLFINE ISIN · INE887E01022 LEI · 335800X5TUU2OAV19X07 BSE.NS Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2026-05-21 Audit Report / Informat…
Country IN India
Listing BSE.NS NGLFINE

About NGL Fine Chem Ltd.

https://www.nglfinechem.com

NGL Fine Chem Ltd. specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates for both veterinary and human healthcare sectors. The company focuses on high-quality chemical synthesis, producing a diverse range of products including anthelmintics, ectoparasiticides, and specialty chemicals. Key products in its portfolio include Nitroxynil, Closantel, Oxyclozanide, and Triclabendazole. Operating with Good Manufacturing Practice (GMP) standards, the firm serves a global clientele, providing customized manufacturing solutions and maintaining a strong emphasis on research and development to enhance process efficiency and product quality. Its technical expertise lies in complex chemical reactions and large-scale production of niche pharmaceutical components.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting Dated May 21, 2026
Audit Report / Information Classification · 86% confidence The document is a formal ‘Outcome of the Board Meeting’ announcement to stock exchanges under SEBI LODR, but the bulk of the text comprises an Independent Auditor’s Report on the consolidated financial results for the quarter and year ended March 31, 2026. It is not a full Annual Report or a simple earnings release; rather, it contains the auditor’s opinion, basis for opinion, and auditor responsibilities. This matches the “Audit Report / Information (AR)” category. FY 2026
2026-05-21 English
Audited Financial Results ( Standalone & Consolidated) Along with Statutory Auditor''s Report
Audit Report / Information Classification · 75% confidence The document is the formal outcome of the Board Meeting under SEBI LODR, principally approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, accompanied by the Independent Auditor’s Report. It is not a full Annual Report (10-K), nor merely a short announcement, but contains the audit opinion and basis, fitting the definition of a standalone Audit Report / Information filing. Thus, it should be classified as AR. FY 2026
2026-05-21 English
Outcome of the Board Meeting held on Thursday, May 21, 2026
Regulatory Filings Classification · 85% confidence The document is an official announcement to stock exchanges under SEBI LODR titled “Outcome of the Board Meeting Dated May 21, 2026.” It informs investors of the board’s approval of audited financial results, dividend recommendation, AGM date, record date, book closure, auditor and director appointments, etc. It does not itself present a full Annual Report (10-K) or Interim/Quarterly Report (IR) in statutory format, nor is it a transcript, proxy statement, or earnings release focused on highlights only. Rather, it is a routine regulatory filing notifying the exchanges of board decisions and enclosed audited results. Accordingly, it falls into the general Regulatory Filings category (RNS).
2026-05-21 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 85% confidence The document consists of formal SEBI (Listing Obligations and Disclosure Requirements) Regulation 29 disclosures to stock exchanges, notifying a board meeting date and agenda items (including considering a final dividend recommendation), and updating that the board will consider recommending a final dividend. It does not provide actual dividend amounts or financial results but is a regulatory compliance announcement. This does not fit into dividend amount notice (DIV) or report publication (RPA) categories and is best classified as a general regulatory filing under SEBI disclosures.
2026-05-20 English
Board Meeting — Board Meeting Intimation
Regulatory Filings Classification · 85% confidence The document is an XBRL-based prior intimation of a Board Meeting under SEBI’s corporate filings taxonomy, providing details of the meeting date, agenda (financial results and dividend), trading window closure, etc. It does not contain actual financial statements (so it is not an Interim or Annual Report), nor is it the financial results release or management discussion. It is a regulatory announcement of an upcoming board meeting (a miscellaneous regulatory filing) and thus falls under the fallback category “Regulatory Filings (RNS).”
2026-05-20 English
NGL Fine Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Further to our communication ....
Regulatory Filings Classification · 65% confidence The document consists of formal intimation letters to BSE and NSE under SEBI Listing Regulations (Reg. 29) notifying (1) a Board meeting to consider and approve audited results and fix AGM/record dates and (2) an update that the Board will consider and recommend a final dividend. There is no actual dividend amount or payment details, nor any change in board composition, nor are full financial statements included. It is a regulatory announcement under SEBI listing rules, serving as a general compliance disclosure rather than an actual financial report, management discussion, or dividend declaration. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-20 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.